What is CJC-1295 Without DAC vs With DAC?

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

CJC-1295 without DAC, also called Modified GRF 1-29, is a strategically engineered analog of growth hormone-releasing hormone (GHRH) designed for in vitro research applications. This 29-amino acid peptide addresses the inherent instability of native GHRH through four targeted amino acid substitutions.

The compound serves as a research tool for investigating growth hormone axis dynamics, somatotroph cell biology, and IGF-1 signaling pathways in controlled laboratory settings.

Key Highlights

• Four amino acid modifications confer enzymatic resistance and extend functional stability from ~7 minutes to 30 minutes-2 hours in biological systems
• Maintains pulsatile GH secretion patterns in research models, preserving physiological feedback mechanisms
• DAC-conjugated variants produce sustained elevation over 6-8 days versus discrete pulses with the no-DAC form
• Applications span somatotroph proliferation studies, receptor signaling research, and metabolic pathway investigations

What Is CJC-1295 Without DAC?

CJC-1295 without DAC consists of a 29-amino acid sequence with molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ and molecular weight of 3,367.9 g/mol.

The peptide derives from the shortest functional fragment of native GHRH that retains full biological activity. This truncation from the native 44-amino acid sequence eliminates extraneous residues while preserving the N-terminal domain required for receptor recognition and activation.

The compound exhibits enhanced resistance to degradation compared to native GHRH while maintaining high affinity for GHRH receptors on somatotroph cells.

The Four Amino Acid Modifications

Each substitution addresses specific stability vulnerabilities identified in native GHRH:

Position 2 (L-Alanine → D-Alanine)

This modification provides the most significant stability enhancement. Dipeptidyl peptidase-4 (DPP-4) cleaves native GHRH between positions 2 and 3 with 82% efficiency within minutes^[1].

The D-alanine stereoisomer creates steric incompatibility with the DPP-4 binding pocket, which recognizes only L-amino acids. This single change accounts for the majority of the extended functional stability.

Position 8 (Asparagine → Glutamine)

Asparagine residues undergo spontaneous deamidation under physiological conditions through intramolecular cyclization. This chemical instability alters peptide backbone structure and disrupts receptor binding geometry.

Glutamine substitution preserves the amide functional group while providing greater resistance to deamidation through its extended side chain that sterically hinders cyclization.

Position 15 (Glycine → Alanine)

This modification targets bioactivity enhancement rather than stability. Alanine substitution increases local hydrophobicity and restricts backbone flexibility, potentially stabilizing the bioactive conformation required for optimal receptor engagement.

Position 27 (Methionine → Leucine)

Methionine residues are highly susceptible to oxidation by reactive oxygen species, forming derivatives that irreversibly alter peptide structure. Leucine substitution eliminates the oxidation-prone thioether group while maintaining hydrophobic character and spatial volume.

This modification proves particularly important for maintaining peptide integrity during lyophilization, reconstitution, and storage in experimental protocols.

Related Product: Buy CJC-1295 + Ipamorelin blend for laboratory research use.

How CJC-1295 Without DAC Differs from the DAC Variant

The Drug Affinity Complex (DAC) modification involves covalent conjugation to a lysine derivative that binds serum albumin through a reactive maleimido group^[2].

This albumin binding dramatically extends circulation time by protecting the peptide from proteolytic degradation and leveraging albumin’s 19-21 day half-life through FcRn-mediated recycling.

Parameter	No DAC	With DAC
Functional Stability	30 min – 2 hours	6-8 days
GH Elevation Duration	2-4 hours	6+ days
IGF-1 Elevation	~24 hours	9-11 days
GH Pattern	Pulsatile	Sustained baseline elevation
Peak Frequency	Preserved	Preserved
Baseline GH	Minimal change	7.5-fold increase

The no-DAC variant creates discrete GH pulses that rise and fall between applications in research models. This temporal pattern closely mimics endogenous GHRH pulsatile release observed in physiological systems.

Pulsatile vs. Sustained GH Secretion Patterns

The distinction between variants extends beyond simple duration to qualitatively different experimental systems.

Modified GRF 1-29’s short functional stability creates periods of low receptor occupancy between exposures. This allows receptor internalization, recycling, and resensitization that maintain physiological responsiveness^[3].

Research demonstrates that pulsatile GH exposure maximizes STAT5b activation, a transcription factor mediating many GH-responsive genes including IGF-1. Continuous exposure reduces STAT5b activation to 10-20% of maximal levels despite higher total GH, suggesting altered signal transduction^[4].

The no-DAC variant proves optimal for research requiring:

• Physiological pulsatile secretion patterns
• Intact feedback mechanism studies
• Acute GH effects on target cells
• Receptor sensitivity investigations
• Pulse-frequency or pulse-amplitude experiments

DAC variants suit research examining sustained GH axis activation and chronic metabolic adaptations over extended timeframes.

Mechanisms of Action in Research Models

GHRH Receptor Binding and Activation

CJC-1295 without DAC mediates biological activity through specific binding to GHRH receptors (GHRHR), members of the class B1 G-protein-coupled receptor superfamily.

These receptors exhibit predominant expression on somatotroph cells within the anterior pituitary, though extrapituitary expression has been documented in brain regions, pancreatic tissue, and cardiac myocytes^[3].

The receptor structure comprises seven transmembrane domains with a large extracellular N-terminal region responsible for peptide ligand recognition. Modified GRF 1-29 retains the N-terminal residues required for initial receptor recognition, explaining its preserved binding affinity despite mid-sequence modifications.

Peptide binding triggers conformational changes involving transmembrane helix 6 movement, opening the intracellular receptor face for G-protein coupling.

Signaling Cascades and Growth Hormone Release

cAMP-PKA Pathway

The primary signaling mechanism involves coupling to Gs-type G proteins that activate adenylyl cyclase. This catalyzes ATP conversion to cyclic AMP, which activates protein kinase A (PKA)^[5].

Key PKA substrates in somatotroph cells include:

• CREB – Phosphorylated CREB binds promoter regions of the growth hormone gene and GHRH receptor gene, increasing transcription
• Voltage-gated calcium channels – PKA phosphorylation increases channel open probability, elevating intracellular Ca²⁺ that triggers secretory granule exocytosis
• Phosphodiesterases – PKA inhibits certain isoforms, creating positive feedback by reducing cAMP degradation

MAPK/ERK Pathway

GHRH receptor activation also engages mitogen-activated protein kinase cascades that mediate proliferative responses in somatotroph cells^[6].

The classical Ras-Raf-MEK-ERK signaling module becomes activated, with ERK1/2 representing terminal effector kinases. These phosphorylate transcription factors, ribosomal S6 kinase, and cytoskeletal proteins.

Research demonstrates this pathway proves particularly important for somatotroph proliferation during pituitary development and in response to growth hormone demand. Pharmacological MEK inhibition blocks GHRH-induced proliferation without affecting cAMP generation, indicating parallel and independent signaling pathways^[6].

Phospholipase C and Calcium Mobilization

GHRHR can couple to Gq/11-type G proteins that activate phospholipase C (PLC). PLC cleaves PIP₂ into IP₃ and DAG second messengers.

IP₃ triggers calcium release from endoplasmic reticulum stores while DAG activates protein kinase C isoforms. This calcium-mobilizing pathway complements the cAMP pathway in driving growth hormone secretion from somatotroph cells.

Third-Party Tested, USA-Made, 99% Purity

Lyophilized peptides for laboratory applications. 99% purity, 100% USA-Made.

Research Applications

Growth Hormone Axis Studies

Somatotroph Cell Biology

Modified GRF 1-29 serves as a tool for investigating mechanisms regulating hypothalamic-pituitary-somatotroph axis function.

GHRH receptor activation stimulates both secretory function and proliferative responses in somatotroph cells. Research demonstrates GHRH induces somatotroph proliferation during pituitary development^[7].

The peptide’s stability advantages over native GHRH make it suitable for multi-day culture experiments where media changes would otherwise be required.

Research applications include:

• Somatotroph differentiation from stem cell precursors
• Proliferative signaling pathway characterization (MAPK/ERK, PI3K/Akt)
• Cell cycle regulation mechanisms
• Transcriptional control via Pit-1 and CREB
• Secretory granule biogenesis studies

Receptor Dynamics and Feedback Regulation

The short functional stability creates research conditions closely mimicking endogenous GHRH pulsatile patterns. Periods of low receptor occupancy between exposures allow receptor internalization and resensitization.

This preservation of feedback loop integrity proves valuable for studies examining:

• Receptor sensitivity and desensitization mechanisms
• Somatostatin interaction effects
• Feedback between GH, IGF-1, and hypothalamic regulators
• Differential effects of pulsatile versus continuous hormone exposure

IGF-1 Signaling Research

Growth hormone’s effects are largely mediated through IGF-1 production stimulation, primarily in hepatocytes but also in peripheral tissues where IGF-1 exerts autocrine and paracrine actions^[8].

Receptor Signaling Pathways

IGF-1 binding to its cognate receptor (IGF-1R), a receptor tyrosine kinase, initiates PI3K/Akt/mTOR and Ras/MAPK cascades. These signaling networks regulate:

• Protein synthesis via mTOR activation
• Glucose uptake through GLUT4 translocation
• Glycogen synthesis
• Cell survival through Akt-mediated phosphorylation of pro-apoptotic proteins
• Transcriptional responses via FOXO transcription factors

Tissue-Specific Responses

Different cell types exhibit distinct responses to IGF-1 elevation in experimental models:

• Skeletal Muscle Cells – IGF-1 stimulates satellite cell activation, myoblast proliferation, and myotube hypertrophy
• Osteoblasts – IGF-1 promotes differentiation and activity while inhibiting osteoclast function
• Adipocytes – Modulates differentiation and metabolism in combination with direct GH lipolytic effects
• Neural Cells – Supports neurogenesis, synaptic plasticity, and neuroprotection against oxidative stress

Technical Considerations for Laboratory Use

Experimental Design Parameters

Concentration Selection

Modified GRF 1-29 exhibits dose-dependent effects on GH secretion in cell culture and tissue models. Dose-response studies should establish threshold concentrations, EC50 values, and maximal effective concentrations for specific experimental objectives.

Temporal Considerations

The functional stability necessitates attention to sampling timing relative to peptide exposure. Growth hormone concentrations in culture media peak within 15-30 minutes, return toward baseline by 2-4 hours, and fully normalize by 4-6 hours in most experimental systems.

Protocols should align measurements with these kinetics based on whether acute peak responses or sustained effects are being investigated.

Storage and Handling

Lyophilized peptides demonstrate stability for four years or longer at -20°C. Acetate salt formulations in solvent show stability for up to one year at -80°C.

Reconstituted solutions should be maintained at 2-8°C and used within validated timeframes to ensure experimental consistency. The leucine-27 substitution protects against oxidative degradation during freeze-thaw cycles.

Analytical Methods

Peptide Quantification

LC-MS/MS following immunoaffinity enrichment can detect concentrations as low as 180 pg/mL in biological matrices. ELISA using GHRH-specific antibodies can also quantify peptide levels, though cross-reactivity validation is required^[9].

Growth Hormone Measurement

Radioimmunoassay and modern ultrasensitive immunoassays enable GH detection in culture supernatants. Important considerations include species-specific antibodies, sampling timing relative to circadian rhythms in intact systems, and stress effects on GH release.

IGF-1 Quantification

IGF-1 measurement typically employs immunoassays following acid-ethanol extraction to dissociate IGF-1 from binding proteins. Mass spectrometry approaches enable simultaneous quantification of multiple IGF system components.

In Vitro Research Applications

Research Area	Potential Applications
Cell Signaling	GHRH receptor activation kinetics, cAMP/PKA pathway characterization, MAPK cascade investigation, calcium mobilization studies
Somatotroph Biology	Proliferation assays, differentiation protocols, secretory granule dynamics, transcriptional regulation
Metabolic Studies	Glucose uptake measurements, lipid metabolism pathways, protein synthesis rates, gene expression profiling
Receptor Pharmacology	Binding affinity determination, receptor desensitization mechanisms, competitive binding studies, structure-activity relationships

Quick Review

CJC-1295 without DAC is a strategically engineered research tool offering enhanced stability and enzymatic resistance compared to native GHRH while preserving physiological pulsatile secretion patterns in experimental models.

The four amino acid substitutions collectively address specific degradation vulnerabilities while maintaining high GHRH receptor affinity. With functional stability of 30 minutes to 2 hours, the no-DAC variant enables discrete GH pulses with preserved feedback regulation.

The choice between DAC and no-DAC variants should align with specific research objectives, with the no-DAC form proving optimal for studies requiring intact pulsatility patterns and receptor dynamics. Applications span somatotroph cell biology, IGF-1 signaling cascades, and metabolic pathway investigations in controlled laboratory settings.

This content is for research and educational purposes only. All BioLongevity Labs peptides are manufactured in USA GMP facilities with triple third-party testing verification and are intended strictly for in vitro laboratory research applications.

References

1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Physiological Society; 2006. https://doi.org/10.1152/ajpendo.00201.2006
2. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. The Endocrine Society; 2005. https://doi.org/10.1210/en.2004-1286
3. Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Springer Science and Business Media LLC; 2025. https://doi.org/10.1007/s11154-025-09952-x
4. Maheshwari HG, Pezzoli SS, Rahim A, Shalet SM, Thorner MO, Baumann G. Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance. American Physiological Society; 2002. https://doi.org/10.1152/ajpendo.00537.2001
5. Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Springer Science and Business Media LLC; 2019. https://doi.org/10.1038/s41392-019-0036-y
6. Zeitler PS, Siriwardana G. Growth Hormone-Releasing Hormone (GHRH) Activates the MAP Kinase Pathway in Rat Somatotrophs. Springer Science and Business Media LLC; 1998. https://doi.org/10.1203/00006450-199804001-00525
7. Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proceedings of the National Academy of Sciences; 2009. https://doi.org/10.1073/pnas.0900977106
8. Arjunan A, Sah DK, Woo M, Song J. Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Springer Science and Business Media LLC; 2023. https://doi.org/10.1186/s13578-023-00966-z
9. Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Springer Science and Business Media LLC; 2016. https://doi.org/10.1007/s00216-016-9377-3